- |||||||||| Alora (estradiol) / AbbVie
"Alora Centres": youth-led model for accelerating HIV testing and treatment among adolescents, Mizoram India (Poster board: 439) - May 2, 2024 - Abstract #AIDS2024AIDS_2537;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- |||||||||| Alora (estradiol) / AbbVie
Alora Pharmaceuticals Executive Leadership Meet and Greet Reception () - Mar 29, 2022 - Abstract #AAN2022AAN_4123;
If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference. Description: Meet and greet with the CEO of Alora/Avion Pharmaceuticals, the head of business development, as well as the chief scientific officer for a reception to introduce the company to the neurology space.
- |||||||||| Alora (estradiol) / AbbVie
2/ Marcela Ot'alora, Michael Mithoefer, Martin A. Lee, Casey Hardison, Andrew Weil, Bruce K. Alexander, Android Jones, Jay Stevens, Earth & Fire Erowids etc.? Very imperfect, a lot of people in who just seek profits. (Twitter) - May 1, 2021
- |||||||||| Vivelle (estradiol transdermal system) / Sanofi, Hisamitsu, Novartis
Journal: Drugs for menopausal symptoms. (Pubmed Central) - Dec 30, 2020
Description: Meet and greet with the CEO of Alora/Avion Pharmaceuticals, the head of business development, as well as the chief scientific officer for a reception to introduce the company to the neurology space. No abstract available
- |||||||||| Vivelle (estradiol transdermal system) / Sanofi, Hisamitsu, Novartis
Journal: Colorectal cancer screening. (Pubmed Central) - Nov 18, 2019
No abstract available No abstract available
- |||||||||| raloxifene hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Raloxifene and Rimostil for Perimenopause-Related Depression (clinicaltrials.gov) - Jun 6, 2015
P4, N=65, Completed,
Trial primary completion date: Feb 2002 --> Jun 2015 Recruiting --> Completed | N=88 --> 65 | Trial primary completion date: Feb 2016 --> Feb 2002
- |||||||||| raloxifene hydrochloride / Generic mfg.
Trial primary completion date: Raloxifene and Rimostil for Perimenopause-Related Depression (clinicaltrials.gov) - Feb 27, 2015
P4, N=88, Recruiting,
Recruiting --> Completed | N=88 --> 65 | Trial primary completion date: Feb 2016 --> Feb 2002 Trial primary completion date: Feb 2015 --> Feb 2016
|
